AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- Varian Medical Systems, Inc. (VAR) and Proxima Therapeutics, Inc. have formed an alliance to increase access to high-dose-rate radiation (HDR) therapy equipment for hospitals interested in offering partial breast irradiation to patients with early-stage breast cancer.
Under the terms of the agreement, Proxima will become the exclusive third-party representative for Varian's recently FDA-cleared MammoSource HDR brachytherapy afterloader, developed specifically to work with Proxima's MammoSite device for treating breast cancer with localized HDR brachytherapy. Varian's MammoSource afterloader will be made available to treatment centers on a fee-for-use basis, subject to minimums.
It has been shown that radiation following surgical removal of the cancer from the breast significantly reduces recurrence. This radiation can be delivered by external beam to the entire breast, external beam to a portion of the breast, or radioactive sources placed temporarily near the tumor site. A study published in the Journal of the National Cancer Institute (August 2003) demonstrated that after 5 years, certain selected ...